This site is intended for healthcare professionals
Blue test tubes arranged in a line, disappearing into the background
  • Home
  • /
  • News
  • /
  • 2014
  • /
  • 08
  • /
  • US Government closes investigation into PLATO tria...
Drug news

US Government closes investigation into PLATO trial of Brilinta and will take no further action - AstraZeneca

Read time: 1 mins
Last updated:19th Aug 2014
Published:19th Aug 2014
Source: Pharmawand

AstraZeneca announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with Brilinta (ticagrelor). The government is not planning any further action.

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news
FDA approves perioperative treatment of neoadjuvant Opdivo (nivolumab) and chemotherapy followed by surgery and adjuvant single-agent Opdivo for resectable NSCLC

Bristol Myers Squibb  announced that the FDA approved Opdivo  (nivolumab) for the treatment of adult patients with resectable (tumors  greater than T4 cm or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent Opdivo as adjuvant treatment after surgery – otherwise referred to as perioperative therapy, which is used before and after surgery.  

3 mins
Drug news
NICE (UK) Positive for latanoprost–netarsudil combination to treat primary open-angle glaucoma or ocular hypertension

Latanoprost–netarsudil is recommended as an option for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension when a prostaglandin analogue alone has not reduced IOP enough

1 min
Drug news
Recordati acquires Enjaymo ( sutimlimab) from Sanofi

Recordati  announces an agreement with Sanofi to acquire the global rights to Enjaymo (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.

1 min
See all news